Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5 q deletion : results of a phase 2 study
暂无分享,去创建一个
A. Stamatoullas | P. Fenaux | L. Adès | C. Gardin | S. Boehrer | G. Laurent | J. Delaunay | N. Vey | O. Beyne-Rauzy | F. Dreyfus | T. Prebet | S. Burcheri | M. Chaury | L. Legros | C. Ravoet | R. M’bida | N. Hoarau
[1] A. Stamatoullas,et al. Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program , 2008 .
[2] H. Dombret,et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.
[3] of lenalidomide , 2008 .
[4] M. Gordon. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .
[5] S. Nimer. Myelodysplastic syndromes. , 2008, Blood.
[6] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[7] J. Maciejewski,et al. Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS). , 2007 .
[8] J. Byrd,et al. Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. , 2007 .
[9] U. Germing,et al. Dependency of Survival on Additional Karyotype Anomalies and Bone Marrow Blast Count in Patients Suffering from Myelodysplastic Syndromes with 5q Deletion. , 2007 .
[10] B. Sander,et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients , 2007, Proceedings of the National Academy of Sciences.
[11] A. List,et al. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome , 2007, Leukemia.
[12] J. Lancet,et al. Treatment of deletion 5q acute myeloid leukemia with lenalidomide , 2007, Leukemia.
[13] A. Giagounidis,et al. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses , 2006, Annals of Hematology.
[14] D. Steensma,et al. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome , 2006, Leukemia.
[15] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[16] P. Schafer,et al. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. , 2006, Leukemia research.
[17] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[18] U. Germing,et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup , 2005, Annals of Hematology.
[19] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.
[20] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Thall,et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. , 2001, Blood.
[22] M. Lübbert,et al. Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.
[23] S. E. Jacobsen,et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. , 2000, Blood.
[24] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[25] L. Michaux,et al. 5q-, twenty-five years later: a synopsis. , 1997, Cancer genetics and cytogenetics.
[26] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[27] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .